Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq in murine acute myeloid leukemia (AML) cells with and without knockdown of Tet1

ABSTRACT: RNA-seq in murine acute myeloid leukemia (AML) cells with and without knockdown of Tet1

PROVIDER: PRJNA479002 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7465484.fastq.gz	Fastqsanger.gz
	SRR7465485.fastq.gz	Fastqsanger.gz
	SRR7465486.fastq.gz	Fastqsanger.gz
	SRR7465487.fastq.gz	Fastqsanger.gz
	SRR7465488.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

RNA-seq in murine acute myeloid leukemia (AML) cells with and without knockdown of Tet1

Project description:To explore the global targets and dissect the mechanism underlying the oncogenic function of TET1 in AML, we performed deep sequencing for mRNA isolated from mouse MLL-ENL-ERtm cells with and without knockdown of Tet1.

2020-06-30 | GSE116548 | GEO

5hmC-seq in human MonoMac6 acute myeloid leukemia (AML) cells with and without knockdown of TET1

Project description:To dissect the mechanism underlying the regulation of TET1 on its target genes in AML, we performed 5hmC-sequencing for genomic DNA isolated from human MonoMac6 AML cells with and without knockdown of TET1.

2020-06-30 | GSE116549 | GEO

5hmC-seq in human MonoMac6 acute myeloid leukemia (AML) cells with and without knockdown of TET1

Project description:5hmC-seq in human MonoMac6 acute myeloid leukemia (AML) cells with and without knockdown of TET1

| PRJNA479001 | ENA

RNA-seq and 5hmC-seq in acute myeloid leukemia (AML) cells with and without knockdown of Tet1

Project description:RNA-seq and 5hmC-seq in acute myeloid leukemia (AML) cells with and without knockdown of Tet1

| PRJNA478995 | ENA

Targeted inhibition of TET1 transcription as a potent therapeutic strategy for acute myeloid leukemia

Project description:Effective therapy of acute myeloid leukemia (AML) remains an unmet need. DNA methylcytosine dioxygenase Ten-eleven translocation 1 (TET1) is a potent oncogene in AML. Through a series of data analysis and drug screening, we identified two compounds (i.e., NSC-311068 and NSC-370284) that selectively suppress TET1 transcription and 5-hydroxymethylcytosine (5hmC) modification, and effectively inhibit cell viability in AML with high level expression of TET1 (i.e., TET1-high AML), including AML carrying t(11q23)/MLL-rearrangements and t(8;21) AML. NSC-311068 and especially NSC-370284 significantly repressed TET1-high AML progression in vivo. UC-514321, an optimized derivative of NSC-370284, exhibited an even more potent therapeutic effect and prolonged the median survival of TET1-high AML mice over three folds. NSC-370284 and its derivative showed strong synergistic effects with standard chemotherapy. NSC-370284 directly targeted STAT3/5, transcriptional activators of TET1, and thus repressed TET1 expression. Our results highlight the therapeutic potential of targeting the STAT/TET1 axis by selective inhibitors in AML treatment.

2018-01-12 | GSE97407 | GEO

Targeted inhibition of STAT/TET1 axis as a potent therapeutic strategy for acute myeloid leukemia

Project description:Effective therapy of acute myeloid leukemia (AML) remains an unmet need. DNA methylcytosine dioxygenase Ten-eleven translocation 1 (TET1) is a critical oncoprotein in AML. Through a series of data analysis and drug screening, we identified two compounds (i.e., NSC-311068 and NSC-370284) that selectively suppress TET1 transcription and 5-hydroxymethylcytosine (5hmC) modification, and effectively inhibit cell viability in AML with high level expression of TET1 (i.e., TET1-high AML), including AML carrying t(11q23)/MLL-rearrangements and t(8;21) AML. NSC-311068 and especially NSC-370284 significantly repressed TET1-high AML progression in vivo. UC-514321, a structural analog of NSC-370284, exhibited a more potent therapeutic effect and prolonged the median survival of TET1-high AML mice over three folds. NSC-370284 and UC-514321 both directly target STAT3/5, transcriptional activators of TET1, and thus repress TET1 expression. They also exhibit strong synergistic effects with standard chemotherapy. Our results highlight the therapeutic potential of targeting the STAT/TET1 axis by selective inhibitors in AML treatment.

2018-01-12 | GSE101480 | GEO

N6-methyladenosine (m6A) sequencing of messenger RNAs in acute myeloid leukemia (AML) cells with and without knockdown of FTO

Project description:To identify potential mRNA targets of FTO whose m6A levels are influenced in acute myeloid leukemia (AML) cells, we conducted m6A-seq for mRNA isolated from MA9.3ITD cells with and without knockdown of FTO

2016-12-20 | GSE84944 | GEO

MicroRNA expression profiles between high and low TET1 expressers with AML

Project description:To obtain the biologic insight of TET1 expression,we analyzed microRNAs expression profiles from 12 AML patients with high TET1 expression and 12 cases with low TET1 expression.

2019-03-05 | GSE103431 | GEO

Sharp2019 - AML

Project description:The paper describes a model of acute myeloid leukaemia. Created by COPASI 4.26 (Build 213) This model is described in the article: Optimal control of acute myeloid leukaemia Jesse A. Sharp, Alexander P Browning, Tarunendu Mapder, Kevin Burrage, Matthew J Simpson Journal of Theoretical Biology 470 (2019) 30–42 Abstract: Acute myeloid leukaemia (AML) is a blood cancer affecting haematopoietic stem cells. AML is routinely treated with chemotherapy, and so it is of great interest to develop optimal chemotherapy treatment strategies. In this work, we incorporate an immune response into a stem cell model of AML, since we find that previous models lacking an immune response are inappropriate for deriving optimal control strategies. Using optimal control theory, we produce continuous controls and bang-bang controls, corre- sponding to a range of objectives and parameter choices. Through example calculations, we provide a practical approach to applying optimal control using Pontryagin’s Maximum Principle. In particular, we describe and explore factors that have a profound influence on numerical convergence. We find that the convergence behaviour is sensitive to the method of control updating, the nature of the control, and to the relative weighting of terms in the objective function. All codes we use to implement optimal control are made available. To cite BioModels Database, please use: BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models . To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication for more information.

2024-09-02 | BIOMD0000000798 | BioModels

RNA-seq in acute myeloid leukemia (AML) cells with and without knockdown of METTL14

Project description:To dissect the mechanism underlying the oncogenic function of METTL14 in AML, we performed deep sequencing for mRNA isolated from MM6 and NB4 cells with and without knockdown of METTL14

2017-12-29 | GSE97443 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data